<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Med.</journal-id>
<journal-title>Frontiers in Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Med.</abbrev-journal-title>
<issn pub-type="epub">2296-858X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmed.2023.1154077</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Medicine</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Prognostic prediction based on histopathologic features of tumor microenvironment in colorectal cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Shi</surname> <given-names>Liang</given-names></name><xref rid="aff1" ref-type="aff"><sup>1</sup></xref><xref rid="aff2" ref-type="aff"><sup>2</sup></xref><xref rid="fn0001" ref-type="author-notes"><sup>&#x2020;</sup></xref></contrib>
<contrib contrib-type="author"><name><surname>Zhang</surname> <given-names>Yuhao</given-names></name><xref rid="aff3" ref-type="aff"><sup>3</sup></xref><xref rid="fn0001" ref-type="author-notes"><sup>&#x2020;</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/949492/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname> <given-names>Hong</given-names></name><xref rid="aff1" ref-type="aff"><sup>1</sup></xref><xref rid="c001" ref-type="corresp"><sup>&#x002A;</sup></xref><uri xlink:href="https://loop.frontiersin.org/people/2189738/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>School of Clinical Medicine, Hebei University</institution>, <addr-line>Baoding, Hebei</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>The First Department of General Surgery, Cangzhou Central Hospital of Hebei Province</institution>, <addr-line>Cangzhou, Hebei</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Neurosurgery, Zhejiang Provincial People's Hospital, Affiliated to Hangzhou Medical College</institution>, <addr-line>Hangzhou, Zhejiang</addr-line>, <country>China</country></aff>
<author-notes>
<fn id="fn0001" fn-type="equal">
<p><sup>&#x2020;</sup>These authors have contributed equally to this work and share first authorship</p>
</fn>
<fn id="fn0002" fn-type="edited-by">
<p>Edited by: Wei Wang, First Affiliated Hospital of Anhui Medical University, China</p>
</fn>
<fn id="fn0003" fn-type="edited-by">
<p>Reviewed by: Shuoyu Xu, Bio-totem Pte Ltd, China; Tsvetelina Velikova, Lozenetz Hospital, Bulgaria</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Hong Wang, <email>wangh_hbu@163.com</email></corresp>
<fn id="fn0004" fn-type="other">
<p>This article was submitted to Gastroenterology, a section of the journal Frontiers in Medicine</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>06</day>
<month>04</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>10</volume>
<elocation-id>1154077</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>01</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>03</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2023 Shi, Zhang and Wang.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Shi, Zhang and Wang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Purpose</title>
<p>To automatically quantify colorectal tumor microenvironment (TME) in hematoxylin and eosin stained whole slide images (WSIs), and to develop a TME signature for prognostic prediction in colorectal cancer (CRC).</p>
</sec>
<sec>
<title>Methods</title>
<p>A deep learning model based on VGG19 architecture and transfer learning strategy was trained to recognize nine different tissue types in whole slide images of patients with CRC. Seven of the nine tissue types were defined as TME components besides background and debris. Then 13 TME features were calculated based on the areas of TME components. A total of 562 patients with gene expression data, survival information and WSIs were collected from The Cancer Genome Atlas project for further analysis. A TME signature for prognostic prediction was developed and validated using Cox regression method. A prognostic prediction model combined the TME signature and clinical variables was also established. At last, gene-set enrichment analysis was performed to identify the significant TME signature associated pathways by querying Gene Ontology database and Kyoto Encyclopedia of Genes and Genomes database.</p>
</sec>
<sec>
<title>Results</title>
<p>The deep learning model achieved an accuracy of 94.2% for tissue type recognition. The developed TME signature was found significantly associated to progression-free survival. The clinical combined model achieved a concordance index of 0.714. Gene-set enrichment analysis revealed the TME signature associated genes were enriched in neuroactive ligand-receptor interaction pathway.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>The TME signature was proved to be a prognostic factor and the associated biologic pathways would be beneficial to a better understanding of TME in CRC patients.</p>
</sec>
</abstract>
<kwd-group>
<kwd>tumor microenvironment</kwd>
<kwd>stroma</kwd>
<kwd>whole slide images</kwd>
<kwd>pathway</kwd>
<kwd>colorectal cancer</kwd>
</kwd-group>
<counts>
<fig-count count="4"/>
<table-count count="5"/>
<equation-count count="0"/>
<ref-count count="33"/>
<page-count count="9"/>
<word-count count="4981"/>
</counts>
</article-meta>
</front>
<body>
<sec id="sec5" sec-type="intro">
<label>1.</label>
<title>Introduction</title>
<p>Colorectal cancer (CRC) is the third most common diagnosed cancer and the second leading cause of cancer death (<xref ref-type="bibr" rid="ref1">1</xref>). Management and treatment of these malignant tumors largely depend on histopathologic diagnosis. Subjective evaluation of histologic slides by experienced pathologists is the gold standard for cancer diagnosis and staging. Molecular and genetic test plays a leading role in the field of quantitative biomarkers (<xref ref-type="bibr" rid="ref2">2</xref>, <xref ref-type="bibr" rid="ref3">3</xref>). Although the tumor node metastasis (TNM) staging system is the basis for treatment decision of CRC patients, different outcomes observed within each stage calls for improved informative markers (<xref ref-type="bibr" rid="ref4">4</xref>, <xref ref-type="bibr" rid="ref5">5</xref>).</p>
<p>Histologic biomarkers focus on the morphological aspects and composition of tumors, rather than their anatomical location and behavior. The substance of the tumor is comprised not only of neoplastic cells but also surrounding stroma which includes immune cells, fibroblasts, signaling molecules and extracellular matrix. These components collectively make up the tumor microenvironment (TME) (<xref ref-type="bibr" rid="ref6">6</xref>, <xref ref-type="bibr" rid="ref7">7</xref>). Survival analyses have demonstrated that valuable aspects of the TME, such as variations in tumor stroma, the presence of tumor budding and host inflammatory response may outperform conventional TNM staging (<xref ref-type="bibr" rid="ref8 ref9 ref10">8&#x2013;10</xref>). Pathologists can recognize these prognostically valuable aspects of the TME, however, the description and quantification of TME is not a routine procedure for pathologists (<xref ref-type="bibr" rid="ref11">11</xref>). Besides, pathologists visually assessed TME on hematoxylin and eosin (H&#x0026;E)-stained sections under the microscope, inevitably causing much discrepancies among pathologists. For example, interobserver agreement of tumor-stroma ratio (TSR) assessment ranges from 0.239 to 0.886 (Cohen&#x2019;s kappa) (<xref ref-type="bibr" rid="ref12 ref13 ref14">12&#x2013;14</xref>). Due to these facts, an automatic TME assessment framework would be valuable, which could lead to better risk stratification, prognosis prediction and treatment support.</p>
<p>The increased availability of digital whole slide images (WSIs) and the successful application of convolutional neural networks (CNNs) in medical imaging, presents an opportunity for fully automatic pathologic assessment of CRC. Kather et al. proposed to use a VGG-based classifier (<xref ref-type="bibr" rid="ref15">15</xref>) to recognize different components in WSIs of CRC patients, and the intermediate activation of the classifier was proved to be related to survival (<xref ref-type="bibr" rid="ref16">16</xref>). Zhao et al. further improved the model by use of larger training data and quantified TSR in WSIs (<xref ref-type="bibr" rid="ref17">17</xref>). Jiao et al. reconsidered the evaluation of TME in colon adenocarcinoma. In addition to stroma component, other tissue types in the tumor mass, especially necrosis and lymphocyte components, are also considered (<xref ref-type="bibr" rid="ref18">18</xref>). However, the biologic pathways associated with the TME features that stratify patients for prognosis are elusive, which becomes one of the barriers preventing computational histopathology into clinical translation.</p>
<p>Therefore, we not only aim to develop a WSI-based TME signature to predict prognosis in a public dataset but also to explore the biological basis of the prognostic TME signature by revealing key pathways associated with the TME signature that confer prognostic significance in CRC patients.</p>
</sec>
<sec id="sec6" sec-type="materials|methods">
<label>2.</label>
<title>Materials and methods</title>
<sec id="sec7">
<label>2.1.</label>
<title>Study design</title>
<p>The overall design of the present study included four steps: tissue segmentation, TME quantification, TME signature development and validation, and pathway/gene identification. First, we developed a deep learning model to identify different TME components on WSI. Second, we calculated some quantitative features to describe the characteristics of TME. Third, we performed survival analysis to assess the prognostic value of the TME features and developed a TME signature for prognosis prediction. Forth, we identified significantly associated genes for annotating individual prognostic TME signature.</p>
</sec>
<sec id="sec8">
<label>2.2.</label>
<title>Data acquisition</title>
<p>The WSIs, clinical data and genome data supported this study were downloaded from The Cancer Genome Atlas (TCGA) database,<xref rid="fn0005" ref-type="fn"><sup>1</sup></xref> the colon adenocarcinoma project (TCGA-COAD) and the rectal adenocarcinoma project (TCGA-READ). The TCGA-COAD project and TCGA-READ projects are two multicenter cohorts, where 461 and 172 patients involved, respectively. The WSIs were H&#x0026;E stained diagnostic slides with &#x201C;.svs&#x201D; format and gene level expression were measured by RNA sequencing data of upper quartile normalized Fragments per Kilobase of transcript per million mapped reads (FPKM-UQ). The follow-up data were extracted from a published study, namely the pan-cancer clinical data resource of TCGA (TCGA-CDR) (<xref ref-type="bibr" rid="ref19">19</xref>). The progression-free survival (PFS) information and clinical variables including age, sex, T stage and N stage were extracted from TCGA-CDR for the following survival analysis.</p>
</sec>
<sec id="sec9">
<label>2.3.</label>
<title>Preprocessing</title>
<p>The WSIs are scanned at 20X (0.5&#x2009;&#x03BC;m/pixel) or 40X (0.25&#x2009;&#x03BC;m/pixel) magnification, so that each image can even contain 100,000&#x2009;&#x00D7;&#x2009;100,000 pixels. However, most of the regions on WSIs are blank area, which do not contribute to TME quantification. To accelerate the WSIs analysis, we used adaptive Otsu method (<xref ref-type="bibr" rid="ref20">20</xref>) for rough foreground segmentation at a low resolution of 112&#x2009;&#x03BC;m/pixel.</p>
<p>According to the genecode_v22_annotation_gene_probeMap document downloaded from the TCGA, we renamed the identifiers of probes to gene symbols, and averaged the gene expression data if multiple probes were mapped to the same gene symbol. Then, we excluded the genes that expressed in less than 20% of samples.</p>
</sec>
<sec id="sec10">
<label>2.4.</label>
<title>Tissue segmentation</title>
<p>In order to realize automatic quantitative analysis of TME, a robust model for TME components recognition is necessary. Kather et al. had published their tissue type classification model of CRC for free (<xref ref-type="bibr" rid="ref16">16</xref>). This model classified the WSIs into nine classes: adipose (ADI), background (BACK), debris (DEB), lymphocytes (LYM), mucus (MUC), muscle (MUS), normal colon mucosa (NORM), cancer-associated stroma (STR) and colorectal adenocarcinoma epithelium (TUM). This model was trained on the NCT-HE-100&#x2009;K dataset and validated on the CRC-VAL-HE-7&#x2009;K dataset<xref rid="fn0006" ref-type="fn"><sup>2</sup></xref> and used the Macenko stain normalization algorithm (<xref ref-type="bibr" rid="ref21">21</xref>) for image preprocessing using the MATLAB software. All images of the two datasets were obtained at 20X (0.5&#x2009;&#x03BC;m/pixel) with a size of 224&#x2009;pixels &#x00D7;&#x2009;224 pixels. The model was built based on VGG-19 architecture and used transfer learning strategy which was pretraining the model on Imagenet dataset for parameters initialization. This model achieved an accuracy of 94.3% in the patch-level classification task on the validation dataset. VGG-19 has been proved to have well tissue classification ability and perform better than Alexnet, Googlenet, Resnet50 and Squeezenet by Kather&#x2019;s study (<xref ref-type="bibr" rid="ref16">16</xref>).</p>
<p>Because of the commercial software restrictions of the MATLAB,<xref rid="fn0007" ref-type="fn"><sup>3</sup></xref> we retained this model using the open source software Python according to the training configurations of Kather et al. In order to apply the trained TME components recognition model on TCGA-COAD and TCGA-READ WSI dataset, we tiled the WSIs at 20X (0.5&#x2009;&#x03BC;m/pixel) into unoverlapped patches with the size of 224&#x2009;pixels &#x00D7;&#x2009;224 pixels.</p>
</sec>
<sec id="sec11">
<label>2.5.</label>
<title>TME features</title>
<p>In the previous study of Zhao et al. (<xref ref-type="bibr" rid="ref17">17</xref>), TSR is defined as a metric of areastroma/(areastroma + areatumor)&#x2009;&#x00D7;&#x2009;100%. In the present study we extended this metric to other TME components besides the BACK and DEB. Furthermore, we also considered relative ratio of the eight TME components in the foreground content as TME features. Thus, we totally defined 13 TME features for further analyses, of which the metrics are listed in <xref rid="tab1" ref-type="table">Table 1</xref>. The correlation between any two TME features was calculated evaluated by Pearson correlation coefficient.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Metric of TME features in the present study.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">TME feature</th>
<th align="left" valign="top">Metric</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">ADI ratio</td>
<td align="left" valign="top">area<sub>adipose</sub>/area<sub>foreground</sub> &#x00D7;&#x2009;100%</td>
</tr>
<tr>
<td align="left" valign="top">LYM ratio</td>
<td align="left" valign="top">area<sub>lymphocytes</sub>/area<sub>foreground</sub> &#x00D7;&#x2009;100%</td>
</tr>
<tr>
<td align="left" valign="top">MUC ratio</td>
<td align="left" valign="top">area<sub>mucus</sub>/area<sub>foreground</sub> &#x00D7;&#x2009;100%</td>
</tr>
<tr>
<td align="left" valign="top">MUS ratio</td>
<td align="left" valign="top">area<sub>muscle</sub>/area<sub>foreground</sub> &#x00D7;&#x2009;100%</td>
</tr>
<tr>
<td align="left" valign="top">NORM ratio</td>
<td align="left" valign="top">area<sub>normal colon mucosa</sub>/area<sub>foreground</sub> &#x00D7;&#x2009;100%</td>
</tr>
<tr>
<td align="left" valign="top">STR ratio</td>
<td align="left" valign="top">area<sub>stroma</sub>/area<sub>foreground</sub> &#x00D7;&#x2009;100%</td>
</tr>
<tr>
<td align="left" valign="top">TUM ratio</td>
<td align="left" valign="top">area<sub>tumor</sub>/area<sub>foreground</sub> &#x00D7;&#x2009;100%</td>
</tr>
<tr>
<td align="left" valign="top">TAR</td>
<td align="left" valign="top">area<sub>adipose</sub>/(area<sub>adipose</sub> +&#x2009;area<sub>tumor</sub>)&#x2009;&#x00D7;&#x2009;100%</td>
</tr>
<tr>
<td align="left" valign="top">TLR</td>
<td align="left" valign="top">area<sub>lymphocytes</sub>/(area<sub>lymphocytes</sub> +&#x2009;area<sub>tumor</sub>)&#x2009;&#x00D7;&#x2009;100%</td>
</tr>
<tr>
<td align="left" valign="top">TMUCR</td>
<td align="left" valign="top">area<sub>mucus</sub>/(area<sub>mucus</sub> +&#x2009;area<sub>tumor</sub>)&#x2009;&#x00D7;&#x2009;100%</td>
</tr>
<tr>
<td align="left" valign="top">TMUSR</td>
<td align="left" valign="top">area<sub>muscle</sub>/(area<sub>muscle</sub> +&#x2009;area<sub>tumor</sub>)&#x2009;&#x00D7;&#x2009;100%</td>
</tr>
<tr>
<td align="left" valign="top">TNR</td>
<td align="left" valign="top">area<sub>normal colon mucosa</sub>/(area<sub>stroma</sub> +&#x2009;area<sub>tumor</sub>)&#x2009;&#x00D7;&#x2009;100%</td>
</tr>
<tr>
<td align="left" valign="top">TSR</td>
<td align="left" valign="top">area<sub>stroma</sub>/(area<sub>stroma</sub> +&#x2009;area<sub>tumor</sub>)&#x2009;&#x00D7;&#x2009;100%</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="sec12">
<label>2.6.</label>
<title>TME signature development and validation</title>
<p>The samples were randomly allocated into a training set and a validation set at a ratio of 7:3. Univariate Cox proportional hazard regression analysis was performed to investigate the association between TME features and PFS in the training set. The significant TME features were then combined by a Cox proportional hazard regression model to generate a TME signature to predict the PFS. The sample were grouped into a high group and a low group by using the median TME signature. Kaplan&#x2013;Meier survival analysis with logrank test was performed to validate the prognostic value of the TME signature. Then a combined model that combined the TME signature and clinical variables using Cox proportional hazard regression were developed to predict the PFS. The time-dependent receiver operating characteristic (ROC) curves were used to evaluated the combined model. The TME signature and combined model were developed in the training set and evaluated in the validation set. The performance of the TME signature and combined model was further evaluated by 10-fold cross validation.</p>
</sec>
<sec id="sec13">
<label>2.7.</label>
<title>Gene-set enrichment analysis</title>
<p>Wilcoxon rank-sum test was performed to identify the significantly associated genes with the TME signature. The significant genes with false discovery rate (FDR)-adjusted <italic>p</italic>&#x2009;&#x003C;&#x2009;0.05 and |log2(fold change)| value &#x003E;0.5 were enriched to find significant pathways using R package &#x201C;clusterProfiler&#x201D; by querying Gene Ontology (GO) annotation database and Kyoto Encyclopedia of Genes and Genomes (KEGG) database. FDR-adjusted <italic>p</italic>&#x2009;&#x003C;&#x2009;0.05 indicated significant enrichment. The significant enriched biologic functions were used to annotate the TME signature.</p>
</sec>
</sec>
<sec id="sec14" sec-type="results">
<label>3.</label>
<title>Results</title>
<sec id="sec15">
<label>3.1.</label>
<title>Patients characteristics</title>
<p>A total of 615 patients with 624 diagnostic WSIs were downloaded from the TCGA-COAD and TCGA-READ (hereafter called TCGA-CRC) project. A total of 616 patients with the gene expression data of the primary tumor were selected from the TCGA-CRC. A total of 590 patients with clinical variables and survival information were extracted from TCGA-CDR study, of which 15 patients with a follow-up time less than 30&#x2009;days were excluded for decreasing the negative effects on accuracy of constructing prognostic models. Finally, 562 patients with WSIs, gene expression, clinical variables and survival information were included for further analyses, as shown in <xref rid="fig1" ref-type="fig">Figure 1A</xref>. The demographic information of these included patients are listed in <xref rid="tab2" ref-type="table">Table 2</xref>.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>The data used in the present study and the process of TME components recognition. <bold>(A)</bold> Venn diagram of the collected data from TCGA-CRC and the percentage of nine tissue types in two cohorts of Kather et al.&#x2019;s study. <bold>(B)</bold> Training a VGG19-based tissue recognition model by transfer learning strategy. <bold>(C)</bold> An example of foreground segmentation and TME components segmentation.</p>
</caption>
<graphic xlink:href="fmed-10-1154077-g001.tif"/>
</fig>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption>
<p>Demographic information of this study.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Variable</th>
<th align="center" valign="top">Value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" colspan="2"><bold>Age, years</bold></td>
</tr>
<tr>
<td align="left" valign="top">Median (interquartile, IQR)</td>
<td align="center" valign="top">68 (58&#x2013;75)</td>
</tr>
<tr>
<td align="left" valign="top">Mean (Standard Deviation, SD)</td>
<td align="center" valign="top">66.2 (12.5)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="2"><bold>Sex</bold></td>
</tr>
<tr>
<td align="left" valign="top">Female</td>
<td align="center" valign="top">259</td>
</tr>
<tr>
<td align="left" valign="top">Male</td>
<td align="center" valign="top">303</td>
</tr>
<tr>
<td align="left" valign="top" colspan="2"><bold>T stage</bold></td>
</tr>
<tr>
<td align="left" valign="top">T1</td>
<td align="center" valign="top">17</td>
</tr>
<tr>
<td align="left" valign="top">T2</td>
<td align="center" valign="top">98</td>
</tr>
<tr>
<td align="left" valign="top">T3</td>
<td align="center" valign="top">388</td>
</tr>
<tr>
<td align="left" valign="top">T4</td>
<td align="center" valign="top">59</td>
</tr>
<tr>
<td align="left" valign="top" colspan="2"><bold>N stage</bold></td>
</tr>
<tr>
<td align="left" valign="top">N0</td>
<td align="center" valign="top">318</td>
</tr>
<tr>
<td align="left" valign="top">N1</td>
<td align="center" valign="top">136</td>
</tr>
<tr>
<td align="left" valign="top">N2</td>
<td align="center" valign="top">108</td>
</tr>
<tr>
<td align="left" valign="top" colspan="2"><bold>Endpoints (uncensored/all)</bold></td>
</tr>
<tr>
<td align="left" valign="top">Progression-free survival</td>
<td align="center" valign="top">148/562</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="sec16">
<label>3.2.</label>
<title>Tissue segmentation</title>
<p>In this study, we used the Otsu method which only costs few seconds (&#x003C;5&#x2009;s) per WSI for the foreground segmentation to accelerate the TME components identification. We retained the TME components recognition model on color normalized NCT-HE-100&#x2009;K dataset and validated it on color normalized CRC-VAL-HE-7&#x2009;K dataset with an accuracy of 94.2%. The heatmap of prediction confusion matrix on CRC-VAL-HE-7&#x2009;K dataset is shown in <xref rid="fig1" ref-type="fig">Figure 1B</xref>, and an example of TME components identified by the model is shown in <xref rid="fig1" ref-type="fig">Figure 1C</xref>. Three patients were found to have no tumor patches on their WSIs, so that the two patients were excluded in the further analyses.</p>
</sec>
<sec id="sec17">
<label>3.3.</label>
<title>TME signature development and validation</title>
<p>In the univariate Cox regression analyses, STR ratio in foreground content and the TSR were found to be significantly (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.05) associated to PFS. The hazard ratio with the 95% confidence interval (CI) of these TME features in Cox regression analyses are summarized in <xref rid="fig2" ref-type="fig">Figure 2A</xref>. STR ratio and TSR were found to be highly correlate, because their correlation coefficient achieved 0.860, as shown in <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S1</xref>. The concordance index (C-index) of the STR ratio and TSR were listed in <xref rid="tab3" ref-type="table">Table 3</xref>. Compared with TSR, STR ratio achieved better predictive ability. The TME signature that combined the STR ratio and TSR was developed by using Cox regression. The weights and <italic>p</italic> values of the two features for TME signature development are listed in <xref rid="tab4" ref-type="table">Table 4</xref>. The p value indicated STR ratio is more important than TSR for TME signature calculation. The C-index of the TME signature was 0.638 (95% CI: 0.574&#x2013;0.701) and 0.625 (95% CI: 0.542&#x2013;0.708) in the training set and validation set, respectively. Kaplan&#x2013;Meier survival curves of the TME signature with logrank test <italic>p</italic>-values were plotted in <xref rid="fig2" ref-type="fig">Figure 2B</xref>. In the multivariate Cox regression analysis, the TME signature was still significantly associated with PFS when considering clinical variables, as shown in <xref rid="fig3" ref-type="fig">Figure 3A</xref>. The combined model achieved a C-index of 0.752 (95% CI: 0.702&#x2013;0.802) and 0.714 (95% CI: 0.642&#x2013;0.786). <xref rid="fig3" ref-type="fig">Figure 3B</xref> showed the time-dependent ROC curves of the combined model for PFS from 1 to 3&#x2009;years. The result of performance comparison indicated that the TME signature performed better than TSR, as shown in <xref rid="tab3" ref-type="table">Table 3</xref>. Moreover, the predictive ability of signature can be further improved by adding clinical information. The mean C-index of the TME signature and combined model in the cross-validation was 0.613 and 0.711, respectively, as shown in <xref rid="tab5" ref-type="table">Table 5</xref>. The result of cross-validation indicated the TME signature and the combined model both had well predictive ability.</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Survival analyses. <bold>(A)</bold> Univariate Cox regression analyses for TME features. <bold>(B)</bold> Kaplan&#x2013;Meier survival analyses for TME signature.</p>
</caption>
<graphic xlink:href="fmed-10-1154077-g002.tif"/>
</fig>
<table-wrap position="float" id="tab3">
<label>Table 3</label>
<caption>
<p>C-index of different models.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Model</th>
<th align="center" valign="top">Training set</th>
<th align="center" valign="top">Validation set</th>
<th align="center" valign="top"><italic>P</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">TME signature</td>
<td align="center" valign="top">0.638</td>
<td align="center" valign="top">0.625</td>
<td align="center" valign="top">-</td>
</tr>
<tr>
<td align="left" valign="top">STR ratio</td>
<td align="center" valign="top">0.637</td>
<td align="center" valign="top">0.604</td>
<td align="center" valign="top">0.136</td>
</tr>
<tr>
<td align="left" valign="top">TSR</td>
<td align="center" valign="top">0.618</td>
<td align="center" valign="top">0.576</td>
<td align="center" valign="top">0.041</td>
</tr>
<tr>
<td align="left" valign="top">Combined model</td>
<td align="center" valign="top">0.752</td>
<td align="center" valign="top">0.714</td>
<td align="center" valign="top">0.012</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>P</italic>-values were used for evaluating the performance difference between the TME signature and the other models in validation set.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap position="float" id="tab4">
<label>Table 4</label>
<caption>
<p>Weights of STR ratio and TSR for calculating TME signature.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Variable</th>
<th align="center" valign="top">Weight</th>
<th align="center" valign="top"><italic>P</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">STR ratio</td>
<td align="center" valign="top">2.667</td>
<td align="center" valign="top">0.028</td>
</tr>
<tr>
<td align="left" valign="top">TSR</td>
<td align="center" valign="top">&#x2212;0.023</td>
<td align="center" valign="top">0.979</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Survival analyses. <bold>(A)</bold> Multivariate Cox regression analyses for TME signature and clinical variables. <bold>(B)</bold> Time-dependent ROC curves of the combined model.</p>
</caption>
<graphic xlink:href="fmed-10-1154077-g003.tif"/>
</fig>
<table-wrap position="float" id="tab5">
<label>Table 5</label>
<caption>
<p>C-index of TME signature and the combined model in 10-fold cross-validation.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Fold</th>
<th align="center" valign="top">TME signature</th>
<th align="center" valign="top">Combined model</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">1</td>
<td align="center" valign="top">0.547</td>
<td align="center" valign="top">0.630</td>
</tr>
<tr>
<td align="left" valign="top">2</td>
<td align="center" valign="top">0.575</td>
<td align="center" valign="top">0.692</td>
</tr>
<tr>
<td align="left" valign="top">3</td>
<td align="center" valign="top">0.604</td>
<td align="center" valign="top">0.762</td>
</tr>
<tr>
<td align="left" valign="top">4</td>
<td align="center" valign="top">0.678</td>
<td align="center" valign="top">0.751</td>
</tr>
<tr>
<td align="left" valign="top">5</td>
<td align="center" valign="top">0.613</td>
<td align="center" valign="top">0.703</td>
</tr>
<tr>
<td align="left" valign="top">6</td>
<td align="center" valign="top">0.625</td>
<td align="center" valign="top">0.691</td>
</tr>
<tr>
<td align="left" valign="top">7</td>
<td align="center" valign="top">0.532</td>
<td align="center" valign="top">0.610</td>
</tr>
<tr>
<td align="left" valign="top">8</td>
<td align="center" valign="top">0.723</td>
<td align="center" valign="top">0.815</td>
</tr>
<tr>
<td align="left" valign="top">9</td>
<td align="center" valign="top">0.677</td>
<td align="center" valign="top">0.769</td>
</tr>
<tr>
<td align="left" valign="top">10</td>
<td align="center" valign="top">0.559</td>
<td align="center" valign="top">0.685</td>
</tr>
<tr>
<td align="left" valign="top">Mean C-index</td>
<td align="center" valign="top">0.613</td>
<td align="center" valign="top">0.711</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="sec18">
<label>3.4.</label>
<title>Gene-set enrichment analysis</title>
<p>A total of 595 genes were found to differently expressed between high- and low-TME signature groups by using rank-sum test corrected by FDR. Compared to the low group, 380 genes were up-regulated and 215 genes were down-regulated, as shown in <xref rid="fig4" ref-type="fig">Figure 4A</xref>. Only 44.2% of the 595 genes were successfully mapped to ENTREZID in GO database. The GO analysis revealed that these TME signature associated genes were enriched in postsynaptic membrane related function and G protein-coupled peptide receptor activity function as shown in <xref rid="fig4" ref-type="fig">Figure 4B</xref>. The KEGG analysis revealed that these genes were enriched in neuroactive ligand-receptor interaction pathway (<xref rid="fig4" ref-type="fig">Figure 4C</xref>). The genes involved in the significantly related GO terms and KEGG pathways were shown in <xref rid="fig4" ref-type="fig">Figure 4D</xref>. The Kaplan&#x2013;Meier survival curves of the genes enriched in the significant GO terms and KEGG were plotted in <xref rid="fig4" ref-type="fig">Figure 4E</xref>.</p>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>Bioinformatics analyses of TME signature associated biologic basics. <bold>(A)</bold> Volcano plot of gene expression between the high-TME signature group and the low-TME signature group. <bold>(B)</bold> The significantly enriched GO terms. <bold>(C)</bold> The significant enriched KEGG pathways. <bold>(D)</bold> Venn diagram of the gene symbols that involved in two significant GO terms and a KEGG pathway. <bold>(E)</bold> Two genes significantly associated to PFS.</p>
</caption>
<graphic xlink:href="fmed-10-1154077-g004.tif"/>
</fig>
</sec>
</sec>
<sec id="sec19" sec-type="discussions">
<label>4.</label>
<title>Discussion</title>
<p>In this study, we presented a workflow of automatic TME quantification on WSIs by using deep learning model, and developed a significant TME signature for PFS prediction. We found that the TME features STR ratio and TSR were significant prognostic factors of PFS in CRC patients. The developed TME signature that combined the STR ratio and TSR still had well predictive ability, when considering clinical variables. The combined model could further improve the prediction. We further annotated the TME signature by gene-set enrichment analysis and found some significantly associated genes were enriched in postsynaptic membrane related function and G protein-coupled peptide receptor activity function. <italic>GABRA5</italic> and <italic>CRHR1</italic>, the TME signature associated genes belong to postsynaptic membrane activity function gene-set and G protein-coupled peptide receptor activity function gene-set respectively, were identified as prognostic factors by Kaplan&#x2013;Meier survival analysis.</p>
<p>It has been reported that TME has a great correlation with the occurrence, development and prognosis of CRC (<xref ref-type="bibr" rid="ref22">22</xref>, <xref ref-type="bibr" rid="ref23">23</xref>). Stromal cells are the major the non-tumor component of TME, which play important roles in evolution of cancers. Recent literature about the TME has shed light on CRC tumorigenesis and the complex interactions between tumor cells and the surrounding stroma (<xref ref-type="bibr" rid="ref24">24</xref>, <xref ref-type="bibr" rid="ref25">25</xref>). Tumor-associated stroma is composed primarily of tumor-associated fibroblasts and extracellular matrix, whose extensive characteristics have been identified relevant roles in promoting tumor growth and invasion (<xref ref-type="bibr" rid="ref26">26</xref>), angiogenesis (<xref ref-type="bibr" rid="ref27">27</xref>), and energy homeostasis (<xref ref-type="bibr" rid="ref28">28</xref>). Therefore, the quantification of TME in CRC might help us formulate a more sensible management and treatment plan for CRC patients. Zhao et al. has developed a deep learning-based TSR using their private data and demonstrated the TSR was significantly associated with OS in CRC patients (<xref ref-type="bibr" rid="ref17">17</xref>). In our study, the Cox regression analysis showed the TSR was also a significant prognostic factor for PFS. The use of OS as an endpoint may undermine clinical studies, because noncancer causes of death do not necessarily reflect tumor biology, invasiveness, or response to treatment. Thus, in consideration of the relatively short follow-up time of TCGA-CRC cohort, we used PFS as an endpoint. Our study revealed that a high STR ratio in TME or high TSR is associated with the poor PFS. STR ratio has more prognostic power than TSR, a well-established signature. Combining STR ratio and TSR would generate a better performed signature. However, these results remain to be validated in other cohorts.</p>
<p>Based on the developed TME signature, we further explored the mechanism associated with the high- and low-TME signature groups. The TME signature associated genes were mainly enriched in Go terms called postsynaptic membrane and G protein-coupled peptide receptor activity. More interesting, both the <italic>GABRA5</italic> and <italic>CRHR1</italic> genes that belong to two different GO terms, were not only significantly associated with PFS but also belong to the same pathway called neuroactive ligand-receptor interaction. Neuroactive ligand-receptor interactions have been shown to be associated with other gastrointestinal cancer (<xref ref-type="bibr" rid="ref29">29</xref>). Yao et al. found that the neuroactive ligand-receptor interaction is significantly associated with the development of colorectal cancer according to the GO and KEGG enrichment analyses (<xref ref-type="bibr" rid="ref30">30</xref>). Whether neuroactive ligand-receptor can directly regulate the formation of stroma and how to further affect tumor progression in colorectal cancer are worthy of further exploration. Develop appropriate regulatory drugs targeting relevant pathways may contribute to the treatment of CRC.</p>
<p>The present study has some limitations. First, our study only included the TCGA-CRC cohort, other independent cohorts are needed for validation of our findings. Second, the prediction accuracy of deep learning model for recognition of TME components should be improved, to ensure the calculated TME features are closer to the real situation. Some new models such as PDBL (<xref ref-type="bibr" rid="ref31">31</xref>), CRCCN-Net (<xref ref-type="bibr" rid="ref32">32</xref>) and Vision Transformer (<xref ref-type="bibr" rid="ref33">33</xref>) are worthy of being using, since they have achieved accuracy of more than 96% in Kather&#x2019;s dataset. Third, nearly half TME signature associated genes failed to be identified by GO and KEGG databases, which may affect the comprehensiveness of functional annotations for TME signature.</p>
<p>In conclusion, the present study validated the feasibility and validity of using deep learning model to quantify the TME, and developed a TME signature for survival prediction. The stroma ratio significantly related to prognosis in CRC was proved once again. The TME signature associated biological pathways were also preliminarily explored. We believe that these findings will be beneficial to the treatment and management of patients with CRC.</p>
</sec>
<sec id="sec20" sec-type="data-availability">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref rid="SM1" ref-type="supplementary-material">Supplementary material</xref>.</p>
</sec>
<sec id="sec21">
<title>Ethics statement</title>
<p>The studies involving human participants were reviewed and approved by the Ethics Committee of Hebei University. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.</p>
</sec>
<sec id="sec22">
<title>Author contributions</title>
<p>LS and HW contributed to conception and design of the study. LS and YZ organized the database and performed the statistical analysis. LS wrote the first draft of the manuscript. LS, YZ, and HW wrote sections of the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="conf1" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ack>
<p>Thanks to the reviewers for their valuable comments and suggestions that will help to improve the quality of our manuscript. We would like to express our most sincere thanks to TCGA and Kather et al. for providing data support.</p>
</ack>
<sec id="sec24" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fmed.2023.1154077/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fmed.2023.1154077/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Image_1.TIF" id="SM1" mimetype="application/tiff" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname> <given-names>H</given-names></name> <name><surname>Ferlay</surname> <given-names>J</given-names></name> <name><surname>Siegel</surname> <given-names>RL</given-names></name> <name><surname>Laversanne</surname> <given-names>M</given-names></name> <name><surname>Soerjomataram</surname> <given-names>I</given-names></name> <name><surname>Jemal</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source>. (<year>2021</year>) <volume>71</volume>:<fpage>209</fpage>&#x2013;<lpage>49</lpage>. doi: <pub-id pub-id-type="doi">10.3322/caac.21660</pub-id>, PMID: <pub-id pub-id-type="pmid">33538338</pub-id></citation></ref>
<ref id="ref2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Connor</surname> <given-names>JP</given-names></name> <name><surname>Jackson</surname> <given-names>A</given-names></name> <name><surname>Asselin</surname> <given-names>M-C</given-names></name> <name><surname>Buckley</surname> <given-names>DL</given-names></name> <name><surname>Parker</surname> <given-names>GJM</given-names></name> <name><surname>Jayson</surname> <given-names>GC</given-names></name></person-group>. <article-title>Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives</article-title>. <source>Lancet Oncol</source>. (<year>2008</year>) <volume>9</volume>:<fpage>766</fpage>&#x2013;<lpage>76</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(08)70196-7</pub-id>, PMID: <pub-id pub-id-type="pmid">18672212</pub-id></citation></ref>
<ref id="ref3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waldman</surname> <given-names>AD</given-names></name> <name><surname>Jackson</surname> <given-names>A</given-names></name> <name><surname>Price</surname> <given-names>SJ</given-names></name> <name><surname>Clark</surname> <given-names>CA</given-names></name> <name><surname>Booth</surname> <given-names>TC</given-names></name> <name><surname>Auer</surname> <given-names>DP</given-names></name> <etal/></person-group>. <article-title>Quantitative imaging biomarkers in neuro-oncology</article-title>. <source>Nat Rev Clin Oncol</source>. (<year>2009</year>) <volume>6</volume>:<fpage>445</fpage>&#x2013;<lpage>54</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrclinonc.2009.92</pub-id></citation></ref>
<ref id="ref4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deschoolmeester</surname> <given-names>V</given-names></name> <name><surname>Baay</surname> <given-names>M</given-names></name> <name><surname>Specenier</surname> <given-names>P</given-names></name> <name><surname>Lardon</surname> <given-names>F</given-names></name> <name><surname>Vermorken</surname> <given-names>JB</given-names></name></person-group>. <article-title>A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy</article-title>. <source>Oncologist</source>. (<year>2010</year>) <volume>15</volume>:<fpage>699</fpage>&#x2013;<lpage>731</lpage>. doi: <pub-id pub-id-type="doi">10.1634/theoncologist.2010-0025</pub-id>, PMID: <pub-id pub-id-type="pmid">20584808</pub-id></citation></ref>
<ref id="ref5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagtegaal</surname> <given-names>ID</given-names></name> <name><surname>Quirke</surname> <given-names>P</given-names></name> <name><surname>Schmoll</surname> <given-names>H-J</given-names></name></person-group>. <article-title>Has the new TNM classification for colorectal cancer improved care?</article-title> <source>Nat Rev Clin Oncol</source>. (<year>2012</year>) <volume>9</volume>:<fpage>119</fpage>&#x2013;<lpage>23</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrclinonc.2011.157</pub-id></citation></ref>
<ref id="ref6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spill</surname> <given-names>F</given-names></name> <name><surname>Reynolds</surname> <given-names>DS</given-names></name> <name><surname>Kamm</surname> <given-names>RD</given-names></name> <name><surname>Zaman</surname> <given-names>MH</given-names></name></person-group>. <article-title>Impact of the physical microenvironment on tumor progression and metastasis</article-title>. <source>Curr Opin Biotechnol</source>. (<year>2016</year>) <volume>40</volume>:<fpage>41</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.copbio.2016.02.007</pub-id>, PMID: <pub-id pub-id-type="pmid">26938687</pub-id></citation></ref>
<ref id="ref7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname> <given-names>A</given-names></name> <name><surname>Allavena</surname> <given-names>P</given-names></name> <name><surname>Sica</surname> <given-names>A</given-names></name> <name><surname>Balkwill</surname> <given-names>F</given-names></name></person-group>. <article-title>Cancer-related inflammation</article-title>. <source>Nature</source>. (<year>2008</year>) <volume>454</volume>:<fpage>436</fpage>&#x2013;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature07205</pub-id></citation></ref>
<ref id="ref8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>S</given-names></name> <name><surname>Huh</surname> <given-names>JW</given-names></name> <name><surname>Lee</surname> <given-names>WY</given-names></name> <name><surname>Yun</surname> <given-names>SH</given-names></name> <name><surname>Kim</surname> <given-names>HC</given-names></name> <name><surname>Cho</surname> <given-names>YB</given-names></name> <etal/></person-group>. <article-title>Prognostic impact of lymphatic invasion, venous invasion, Perineural invasion and tumor budding in rectal cancer treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal excision</article-title>. <source>Dis Colon Rectum</source>. (<year>2022</year>) doi: <pub-id pub-id-type="doi">10.1097/DCR.0000000000002266</pub-id> [Epub ahead of print]., PMID: <pub-id pub-id-type="pmid">35195558</pub-id></citation></ref>
<ref id="ref9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname> <given-names>X</given-names></name> <name><surname>Xiao</surname> <given-names>F</given-names></name> <name><surname>Chen</surname> <given-names>Y-Y</given-names></name> <name><surname>Yuan</surname> <given-names>JP</given-names></name> <name><surname>Liu</surname> <given-names>XH</given-names></name> <name><surname>Wang</surname> <given-names>LW</given-names></name> <etal/></person-group>. <article-title>Computerized assessment of the tumor-stromal ratio and proposal of a novel Nomogram for predicting survival in invasive breast cancer</article-title>. <source>J Cancer</source>. (<year>2021</year>) <volume>12</volume>:<fpage>3427</fpage>&#x2013;<lpage>38</lpage>. doi: <pub-id pub-id-type="doi">10.7150/jca.55750</pub-id>, PMID: <pub-id pub-id-type="pmid">33995621</pub-id></citation></ref>
<ref id="ref10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname> <given-names>C</given-names></name> <name><surname>Roxburgh</surname> <given-names>C</given-names></name> <name><surname>Anderson</surname> <given-names>J</given-names></name> <name><surname>McKee</surname> <given-names>RF</given-names></name> <name><surname>Foulis</surname> <given-names>AK</given-names></name> <name><surname>Horgan</surname> <given-names>PG</given-names></name> <etal/></person-group>. <article-title>Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer</article-title>. <source>Br J Surg</source>. (<year>2012</year>) <volume>99</volume>:<fpage>287</fpage>&#x2013;<lpage>94</lpage>. doi: <pub-id pub-id-type="doi">10.1002/bjs.7755</pub-id>, PMID: <pub-id pub-id-type="pmid">22086662</pub-id></citation></ref>
<ref id="ref11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hynes</surname> <given-names>SO</given-names></name> <name><surname>Coleman</surname> <given-names>HG</given-names></name> <name><surname>Kelly</surname> <given-names>PJ</given-names></name> <name><surname>Irwin</surname> <given-names>S</given-names></name> <name><surname>O'Neill</surname> <given-names>RF</given-names></name> <name><surname>Gray</surname> <given-names>RT</given-names></name> <etal/></person-group>. <article-title>Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study</article-title>. <source>Histopathology</source>. (<year>2017</year>) <volume>71</volume>:<fpage>12</fpage>&#x2013;<lpage>26</lpage>. doi: <pub-id pub-id-type="doi">10.1111/his.13181</pub-id>, PMID: <pub-id pub-id-type="pmid">28165633</pub-id></citation></ref>
<ref id="ref12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Pelt</surname> <given-names>GW</given-names></name> <name><surname>Kj&#x00E6;r-Frifeldt</surname> <given-names>S</given-names></name> <name><surname>van Krieken</surname> <given-names>JHJ</given-names></name> <name><surname>al Dieri</surname> <given-names>R</given-names></name> <name><surname>Morreau</surname> <given-names>H</given-names></name> <name><surname>Tollenaar</surname> <given-names>RAEM</given-names></name> <etal/></person-group>. <article-title>Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations</article-title>. <source>Virchows Arch</source>. (<year>2018</year>) <volume>473</volume>:<fpage>405</fpage>&#x2013;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00428-018-2408-z</pub-id>, PMID: <pub-id pub-id-type="pmid">30030621</pub-id></citation></ref>
<ref id="ref13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Courrech Staal</surname> <given-names>EFW</given-names></name> <name><surname>Smit</surname> <given-names>VT</given-names></name> <name><surname>van Velthuysen</surname> <given-names>M-LF</given-names></name> <name><surname>Spitzer-Naaykens</surname> <given-names>JMJ</given-names></name> <name><surname>Wouters</surname> <given-names>MWJM</given-names></name> <name><surname>Mesker</surname> <given-names>WE</given-names></name> <etal/></person-group>. <article-title>Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies</article-title>. <source>Eur J Cancer</source>. (<year>2011</year>) <volume>47</volume>:<fpage>375</fpage>&#x2013;<lpage>82</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejca.2010.09.043</pub-id>, PMID: <pub-id pub-id-type="pmid">21036599</pub-id></citation></ref>
<ref id="ref14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Pelt</surname> <given-names>GW</given-names></name> <name><surname>Sandberg</surname> <given-names>TP</given-names></name> <name><surname>Morreau</surname> <given-names>H</given-names></name> <name><surname>Gelderblom</surname> <given-names>H</given-names></name> <name><surname>van Krieken</surname> <given-names>JHJM</given-names></name> <name><surname>Tollenaar</surname> <given-names>RAEM</given-names></name> <etal/></person-group>. <article-title>The tumour-stroma ratio in colon cancer: the biological role and its prognostic impact</article-title>. <source>Histopathology</source>. (<year>2018</year>) <volume>73</volume>:<fpage>197</fpage>&#x2013;<lpage>206</lpage>. doi: <pub-id pub-id-type="doi">10.1111/his.13489</pub-id>, PMID: <pub-id pub-id-type="pmid">29457843</pub-id></citation></ref>
<ref id="ref15"><label>15.</label><citation citation-type="other"><person-group person-group-type="author"><name><surname>Simonyan</surname> <given-names>K</given-names></name> <name><surname>Zisserman</surname> <given-names>A.</given-names></name></person-group> Very deep convolutional networks for large-scale image recognition. arXiv [Preprint]: arXiv:14091556. (<year>2014</year>).</citation></ref>
<ref id="ref16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kather</surname> <given-names>JN</given-names></name> <name><surname>Krisam</surname> <given-names>J</given-names></name> <name><surname>Charoentong</surname> <given-names>P</given-names></name> <name><surname>Luedde</surname> <given-names>T</given-names></name> <name><surname>Herpel</surname> <given-names>E</given-names></name> <name><surname>Weis</surname> <given-names>CA</given-names></name> <etal/></person-group>. <article-title>Predicting survival from colorectal cancer histology slides using deep learning: a retrospective multicenter study</article-title>. <source>PLoS Med</source>. (<year>2019</year>) <volume>16</volume>:<fpage>e1002730</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pmed.1002730</pub-id>, PMID: <pub-id pub-id-type="pmid">30677016</pub-id></citation></ref>
<ref id="ref17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>K</given-names></name> <name><surname>Li</surname> <given-names>Z</given-names></name> <name><surname>Yao</surname> <given-names>S</given-names></name> <name><surname>Wang</surname> <given-names>Y</given-names></name> <name><surname>Wu</surname> <given-names>X</given-names></name> <name><surname>Xu</surname> <given-names>Z</given-names></name> <etal/></person-group>. <article-title>Artificial intelligence quantified tumour-stroma ratio is an independent predictor for overall survival in resectable colorectal cancer</article-title>. <source>EBioMedicine</source>. (<year>2020</year>) <volume>61</volume>:<fpage>103054</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2020.103054</pub-id>, PMID: <pub-id pub-id-type="pmid">33039706</pub-id></citation></ref>
<ref id="ref18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname> <given-names>Y</given-names></name> <name><surname>Li</surname> <given-names>J</given-names></name> <name><surname>Qian</surname> <given-names>C</given-names></name> <name><surname>Fei</surname> <given-names>S</given-names></name></person-group>. <article-title>Deep learning-based tumor microenvironment analysis in colon adenocarcinoma histopathological whole-slide images</article-title>. <source>Comput Methods Prog Biomed</source>. (<year>2021</year>) <volume>204</volume>:<fpage>106047</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmpb.2021.106047</pub-id>, PMID: <pub-id pub-id-type="pmid">33789213</pub-id></citation></ref>
<ref id="ref19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>J</given-names></name> <name><surname>Lichtenberg</surname> <given-names>T</given-names></name> <name><surname>Hoadley</surname> <given-names>KA</given-names></name> <name><surname>Poisson</surname> <given-names>LM</given-names></name> <name><surname>Lazar</surname> <given-names>AJ</given-names></name> <name><surname>Cherniack</surname> <given-names>AD</given-names></name> <etal/></person-group>. <article-title>An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics</article-title>. <source>Cells</source>. (<year>2018</year>) <volume>173</volume>:<fpage>400</fpage>&#x2013;<lpage>416.e11</lpage>. e11. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2018.02.052</pub-id>, PMID: <pub-id pub-id-type="pmid">29625055</pub-id></citation></ref>
<ref id="ref20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Otsu</surname> <given-names>N</given-names></name></person-group>. <article-title>A threshold selection method from gray-level histograms</article-title>. <source>IEEE Trans Syst Man Cybern</source>. (<year>1979</year>) <volume>9</volume>:<fpage>62</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1109/TSMC.1979.4310076</pub-id></citation></ref>
<ref id="ref21"><label>21.</label><citation citation-type="other"><person-group person-group-type="author"><name><surname>Macenko</surname> <given-names>M</given-names></name> <name><surname>Niethammer</surname> <given-names>M</given-names></name> <name><surname>Marron</surname> <given-names>JS</given-names></name> <name><surname>Borland</surname> <given-names>D</given-names></name> <name><surname>Woosley</surname> <given-names>JT</given-names></name> <name><surname>Guan</surname> <given-names>X</given-names></name> <etal/></person-group>., editors. A method for normalizing histology slides for quantitative analysis. In: <italic>2009 IEEE international symposium on biomedical imaging: From nano to macro</italic>; (<year>2009</year>): IEEE.</citation></ref>
<ref id="ref22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>JH</given-names></name> <name><surname>McMillan</surname> <given-names>DC</given-names></name> <name><surname>Powell</surname> <given-names>AG</given-names></name> <name><surname>Richards</surname> <given-names>CH</given-names></name> <name><surname>Horgan</surname> <given-names>PG</given-names></name> <name><surname>Edwards</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer</article-title>. <source>Clin Cancer Res</source>. (<year>2015</year>) <volume>21</volume>:<fpage>882</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1686</pub-id>, PMID: <pub-id pub-id-type="pmid">25473000</pub-id></citation></ref>
<ref id="ref23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hinshaw</surname> <given-names>DC</given-names></name> <name><surname>Shevde</surname> <given-names>LA</given-names></name></person-group>. <article-title>The tumor microenvironment innately modulates cancer progression</article-title>. <source>Cancer Res</source>. (<year>2019</year>) <volume>79</volume>:<fpage>4557</fpage>&#x2013;<lpage>66</lpage>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-3962</pub-id>, PMID: <pub-id pub-id-type="pmid">31350295</pub-id></citation></ref>
<ref id="ref24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Atiya</surname> <given-names>H</given-names></name> <name><surname>Frisbie</surname> <given-names>L</given-names></name> <name><surname>Pressimone</surname> <given-names>C</given-names></name> <name><surname>Coffman</surname> <given-names>L</given-names></name></person-group>. <article-title>Mesenchymal stem cells in the tumor microenvironment</article-title>. <source>Tumor Microenviron Non-Hematopoiet Cells</source>. (<year>2020</year>) <volume>1234</volume>:<fpage>31</fpage>&#x2013;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-3-030-37184-5_3</pub-id></citation></ref>
<ref id="ref25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>M</given-names></name> <name><surname>Zhao</surname> <given-names>J</given-names></name> <name><surname>Zhang</surname> <given-names>L</given-names></name> <name><surname>Wei</surname> <given-names>F</given-names></name> <name><surname>Lian</surname> <given-names>Y</given-names></name> <name><surname>Wu</surname> <given-names>Y</given-names></name> <etal/></person-group>. <article-title>Role of tumor microenvironment in tumorigenesis</article-title>. <source>J Cancer</source>. (<year>2017</year>) <volume>8</volume>:<fpage>761</fpage>&#x2013;<lpage>73</lpage>. doi: <pub-id pub-id-type="doi">10.7150/jca.17648</pub-id>, PMID: <pub-id pub-id-type="pmid">28382138</pub-id></citation></ref>
<ref id="ref26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Wever</surname> <given-names>O</given-names></name> <name><surname>Mareel</surname> <given-names>M</given-names></name></person-group>. <article-title>Role of tissue stroma in cancer cell invasion</article-title>. <source>J Pathol</source>. (<year>2003</year>) <volume>200</volume>:<fpage>429</fpage>&#x2013;<lpage>47</lpage>. doi: <pub-id pub-id-type="doi">10.1002/path.1398</pub-id></citation></ref>
<ref id="ref27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koshida</surname> <given-names>Y</given-names></name> <name><surname>Kuranami</surname> <given-names>M</given-names></name> <name><surname>Watanabe</surname> <given-names>M</given-names></name></person-group>. <article-title>Interaction between stromal fibroblasts and colorectal cancer cells in the expression of vascular endothelial growth factor</article-title>. <source>J Surg Res</source>. (<year>2006</year>) <volume>134</volume>:<fpage>270</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jss.2006.02.025</pub-id>, PMID: <pub-id pub-id-type="pmid">16600304</pub-id></citation></ref>
<ref id="ref28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koukourakis</surname> <given-names>MI</given-names></name> <name><surname>Giatromanolaki</surname> <given-names>A</given-names></name> <name><surname>Harris</surname> <given-names>AL</given-names></name> <name><surname>Sivridis</surname> <given-names>E</given-names></name></person-group>. <article-title>Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma</article-title>. <source>Cancer Res</source>. (<year>2006</year>) <volume>66</volume>:<fpage>632</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3260</pub-id></citation></ref>
<ref id="ref29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>J</given-names></name> <name><surname>Zhang</surname> <given-names>Q</given-names></name> <name><surname>Wang</surname> <given-names>M</given-names></name> <name><surname>Liang</surname> <given-names>SJ</given-names></name> <name><surname>Huang</surname> <given-names>HY</given-names></name> <name><surname>Xie</surname> <given-names>L</given-names></name> <etal/></person-group>. <article-title>Comprehensive analysis of tumor mutation burden and immune microenvironment in gastric cancer</article-title>. <source>Biosci Rep</source>. (<year>2021</year>) <volume>41</volume>:<fpage>BSR20203336</fpage>. doi: <pub-id pub-id-type="doi">10.1042/BSR20203336</pub-id>, PMID: <pub-id pub-id-type="pmid">33492335</pub-id></citation></ref>
<ref id="ref30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname> <given-names>H</given-names></name> <name><surname>Li</surname> <given-names>C</given-names></name> <name><surname>Tan</surname> <given-names>X</given-names></name></person-group>. <article-title>An age stratified analysis of the biomarkers in patients with colorectal cancer</article-title>. <source>Sci Rep</source>. (<year>2021</year>) <volume>11</volume>:<fpage>1</fpage>&#x2013;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-021-01850-x</pub-id>, PMID: <pub-id pub-id-type="pmid">34789836</pub-id></citation></ref>
<ref id="ref31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>J</given-names></name> <name><surname>Han</surname> <given-names>G</given-names></name> <name><surname>Pan</surname> <given-names>X</given-names></name> <name><surname>Liu</surname> <given-names>Z</given-names></name> <name><surname>Chen</surname> <given-names>H</given-names></name> <name><surname>Li</surname> <given-names>D</given-names></name> <etal/></person-group>. <article-title>PDBL: improving Histopathological tissue classification with plug-and-play pyramidal deep-broad learning</article-title>. <source>IEEE T Med Imaging</source>. (<year>2022</year>) <volume>41</volume>:<fpage>2252</fpage>&#x2013;<lpage>62</lpage>. doi: <pub-id pub-id-type="doi">10.1109/TMI.2022.3161787</pub-id>, PMID: <pub-id pub-id-type="pmid">35320093</pub-id></citation></ref>
<ref id="ref32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname> <given-names>A</given-names></name> <name><surname>Vishwakarma</surname> <given-names>A</given-names></name> <name><surname>Bajaj</surname> <given-names>V</given-names></name></person-group>. <article-title>Crccn-net: automated framework for classification of colorectal tissue using histopathological images</article-title>. <source>Biomed Signal Proces</source>. (<year>2023</year>) <volume>79</volume>:<fpage>104172</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bspc.2022.104172</pub-id></citation></ref>
<ref id="ref33"><label>33.</label><citation citation-type="other"><person-group person-group-type="author"><name><surname>Zeid</surname> <given-names>MA</given-names></name> <name><surname>El-Bahnasy</surname> <given-names>K</given-names></name> <name><surname>Abo-Youssef</surname> <given-names>SE</given-names></name></person-group>. Multiclass colorectal cancer histology images classification using vision transformers. In: <italic>2021 tenth international conference on intelligent computing and information systems (ICICIS)</italic>. IEEE, (<year>2021</year>). 224&#x2013;230.</citation></ref>
</ref-list>
<fn-group>
<fn id="fn0005">
<p><sup>1</sup><ext-link xlink:href="https://portal.gdc.cancer.gov" ext-link-type="uri">https://portal.gdc.cancer.gov</ext-link>
</p>
</fn>
<fn id="fn0006">
<p><sup>2</sup><ext-link xlink:href="http://dx.doi.org/10.5281/zenodo.1214456" ext-link-type="uri">http://dx.doi.org/10.5281/zenodo.1214456</ext-link>
</p>
</fn>
<fn id="fn0007">
<p><sup>3</sup><ext-link xlink:href="https://www.mathworks.com/" ext-link-type="uri">https://www.mathworks.com/</ext-link>
</p>
</fn>
</fn-group>
</back>
</article>